Protecting Innovation to Empower Global Impact
Our intellectual property portfolio safeguards our delivery platforms, therapeutic modalities, and clinical programmes, enabling strategic collaborations and global patient reach.
Property Strategy: Dawn Intellectual Property
At Dawn Therapeutics, intellectual property (IP) is a core strategic asset. We build our IP portfolio to:
Protect proprietary delivery technologies for CNS, cartilage, muscle, and liver targeting.
Secure therapeutic candidates across multiple rare and complex disease areas.
Enable exclusive commercial rights for our partners and licensees.
Strengthen market position with broad territorial coverage.
Key Areas of Patent Protection
Our patent filings cover:
1. Dual Platform Delivery Technologies
Dawn Therapeutics is built on two complementary platforms designed to solve the core barriers in gene therapy: tissue targeting, immune response, and manufacturing scalability.
- Stealth Lentiviral Vector (sLV): A third-generation lentiviral system engineered for direct in vivo delivery, with immune-evasion features and a built-in safety switch.
- Immunologically Targeted LNP (iLNP): A precision lipid nanoparticle platform for targeted delivery to difficult tissues including brain, joints, and cartilage.
Together, these platforms support safer, more precise, and more scalable gene therapy development.
2. Precision Targeting and Payload Flexibility
Dawn’s iLNP platform is designed for tissue-specific delivery with broad payload flexibility.
- Proprietary targeting ligands, including transferrin receptor aptamer and joint-targeting antibody approaches, support delivery across the blood-brain barrier and into joint/cartilage tissues.
- The platform can carry DNA, RNA, and gene-editing components, enabling use across multiple therapeutic strategies.
- In preclinical studies, Dawn reports strong targeting signals in joints and cartilage, plus effective CNS delivery in animal models.
This is a platform architecture for multiple programmes, not a single-product formulation.
3. Manufacturing and CMC Execution Model
- Virocell Biologics is the preferred GMP partner for DTX-101 lentiviral production (MSA in progress).
- Pharmidex supports toxicology work packages, including dose-ranging and repeat-dose studies.
- Cell and Gene Therapy Catapult (CGT Catapult) supports non-clinical strategy, CMC gap analysis, target product profile, and MHRA regulatory planning.
4. Development Pipeline and Programme Expansion
- DTX-101 (Hurler syndrome / MPS1H) is the lead programme and has shown preclinical proof of concept, including biomarker improvement in animal models.
- The 24-month plan is structured around milestone-based work packages and formal Go/No-Go gates.
- Pipeline expansion is planned into:
- Wilson’s disease
- Urea cycle disorders
- CNS disorders (for example Parkinson’s or Huntington’s)
- Joint/cartilage diseases (including osteoarthritis)
Patent Coverage & Territories
Our portfolio includes filed and granted patents in:
North America
United States, Canada.
Europe
EU member states, UK, Switzerland, Norway.
Asia-Pacific
Japan, China, South Korea, Australia, Singapore.
Other Regions
Middle East, South America, Africa — filed strategically depending on market opportunity.
Innovation Pipeline Protection
- Platform-Level Protection: Secures our ability to deploy the same delivery platform across multiple indications.
- Indication-Specific Patents: Protects individual therapeutic programmes and disease applications.
- Freedom-to-Operate (FTO) Analyses: Conducted regularly to avoid infringement risks.
Why Our IP Matters to Partners
- Enables exclusive rights in defined markets.
- Strengthens licensing potential with robust legal protection.
- Enhances valuation for investment and acquisition opportunities.
- Supports regulatory exclusivity alongside patent life.
IP Position and Portfolio Defensibility
Dawn Therapeutics is building a layered IP and know-how position around its lead programme and delivery platforms. Public pages provide a high-level summary only. Detailed filing strategy, claim structure, and jurisdiction coverage are reserved for qualified investor and partner review under NDA.
Portfolio highlights
- ✓Priority PCT protection for DTX-101 (MPS1H) and associated delivery constructs
- ✓Additional filings in preparation covering promoter architecture, safety and stealth features, and tissue-targeting chemistries
- ✓Manufacturing, analytics, and release methods protected through controlled trade secrets and restricted SOP access
FTO and legal risk management
Dawn maintains a structured freedom-to-operate review process with external counsel and updates IP risk assessments at key development gates. Detailed legal opinions and claim maps are shared only during diligence.
Confidentiality and access
- iNo patent numbers or unpublished filing details are disclosed publicly
- iNon-confidential summaries are available for early investor discussions
- iFull portfolio materials are available to qualified parties under NDA
